Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Weather and pollution affect outcomes after heart attack

Pollution and weather influence outcomes after a heart attack, according to research presented at ESC Congress today by Ms Aneta Cislak, research fellow in the Silesian Centre for Heart Diseases, Medical University of Silesia in Zabrze, Poland.

29 Aug 2015

Nitroglycerin can be repurposed to treat cancer, researchers find

For over a century, nitroglycerin has been used medically - particularly in the treatment of angina, or chest pain. It is a safe, cheap and effective treatment. Now, according to the latest study in ecancermedicalscience, researchers find that nitroglycerin is the latest in a series of medicines that could be repurposed to treat cancer.

27 Aug 2015

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Liver transplantation is currently the only established treatment for patients with end stage liver failure. However, this treatment is limited by the shortage of donors and the conditional integrity and suitability of the available organs. Transplanting donor hepatocytes (liver cells) into the liver as an alternative to liver transplantation also has drawbacks as the rate of survival of primary hepatocytes is limited and often severe complications can result from the transplantation procedure.

27 Aug 2015

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension.

10 Aug 2015

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

In a collaborative study between Sanford Burnham Prebys Medical Discovery Institute and the Argonne National Laboratory, scientists have used a highly specialized X-ray crystallography technique to solve the protein structure of hypoxia-inducible factors (HIFs), important regulators of a tumor's response to low oxygen (hyopoxia).

6 Aug 2015

Implanted biochemical sensor could allow doctors to better monitor, adjust cancer treatments

In the battle against cancer, which kills nearly 8 million people worldwide each year, doctors have in their arsenal many powerful weapons, including various forms of chemotherapy and radiation. What they lack, however, is good reconnaissance — a reliable way to obtain real-time data about how well a particular therapy is working for any given patient.

5 Aug 2015

Study provides mechanism for EDNRB gene's role in adaptation to life at high altitudes

Ethiopians have lived at high altitudes for thousands of years, providing a natural experiment for studying human adaptations to low oxygen, a condition known as hypoxia. One factor that may enable Ethiopians to tolerate high altitudes and hypoxia is the endothelin receptor type B (EDNRB) gene.

4 Aug 2015

Recipients of GSA poster awards announced at 20th International C. elegans Meeting

The Genetics Society of America and the C. elegans research community are pleased to announce the recipients of the GSA poster awards at the 20th International C. elegans Meeting, which took place at the University of California, Los Angeles, June 24-28, 2015.

28 Jul 2015

UC San Diego researchers identify pivotal player in diabetic kidney disease

Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease.

23 Jul 2015

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

New 'smart insulin patch' could help patients suffering from diabetes

Painful insulin injections could become a thing of the past for the millions of Americans who suffer from diabetes, thanks to a new invention from researchers at the University of North Carolina and NC State, who have created the first "smart insulin patch" that can detect increases in blood sugar levels and secrete doses of insulin into the bloodstream whenever needed.

23 Jun 2015

UT Southwestern scientists devise new technique to identify cell that replenishes adult heart muscle

Regenerative medicine researchers at UT Southwestern Medical Center have identified a cell that replenishes adult heart muscle by using a new cell lineage-tracing technique they devised.

23 Jun 2015

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy.

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Scientists forecast an average 'dead zone' in Gulf of Mexico this year

Scientists are expecting that this year's Gulf of Mexico hypoxic zone, also called the "dead zone," will be approximately 5,483 square miles or about the size of Connecticut-the same as it has averaged over the last several years.

19 Jun 2015

La Jolla Institute researchers identify molecular pathway that maintains Treg cells' function

Regulatory T cells (Treg cells) are part of the system of checks and balances that prevents the immune response from going overboard and causing autoimmune disease. Although critically important for shaping the immune response and maintaining self-tolerance, how they hold on to their immune-suppressive powers had remained unclear.

17 Jun 2015

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.

9 Jun 2015

Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today.

1 Jun 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015